CN109790159A - 抗流感病毒嘧啶衍生物 - Google Patents

抗流感病毒嘧啶衍生物 Download PDF

Info

Publication number
CN109790159A
CN109790159A CN201780054195.XA CN201780054195A CN109790159A CN 109790159 A CN109790159 A CN 109790159A CN 201780054195 A CN201780054195 A CN 201780054195A CN 109790159 A CN109790159 A CN 109790159A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
regulations
correcting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780054195.XA
Other languages
English (en)
Other versions
CN109790159B (zh
Inventor
熊剑
龙超峰
王晶晶
陈小新
陈新海
谢程
李鹏
彭宣嘉
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Priority to CN201910800685.0A priority Critical patent/CN110627784B/zh
Priority to CN201910800902.6A priority patent/CN110623958B/zh
Publication of CN109790159A publication Critical patent/CN109790159A/zh
Application granted granted Critical
Publication of CN109790159B publication Critical patent/CN109790159B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

本发公开了一类抗流感病毒化合物，及其在制备治疗与流感病毒相关药物中的应用。具体公开了式(Ⅰ)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201780054195.XA 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物 Active CN109790159B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910800685.0A CN110627784B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201910800902.6A CN110623958B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610804101 2016-09-05
CN2016108041013 2016-09-05
CN201611238759 2016-12-28
CN2016112387599 2016-12-28
PCT/CN2017/100461 WO2018041263A1 (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910800685.0A Division CN110627784B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201910800902.6A Division CN110623958B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN109790159A true CN109790159A (zh) 2019-05-21
CN109790159B CN109790159B (zh) 2020-01-14

Family

ID=61300177

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910800685.0A Active CN110627784B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201780054195.XA Active CN109790159B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201910800902.6A Active CN110623958B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910800685.0A Active CN110627784B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910800902.6A Active CN110623958B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Country Status (14)

Country Link
US (3) US11136319B2 (zh)
EP (1) EP3502112A4 (zh)
JP (1) JP6838773B2 (zh)
KR (1) KR102312088B1 (zh)
CN (3) CN110627784B (zh)
AU (1) AU2017320088B2 (zh)
BR (1) BR112019004420A2 (zh)
CA (1) CA3035680C (zh)
IL (1) IL265166B (zh)
MX (1) MX2019002541A (zh)
RU (1) RU2727772C1 (zh)
SG (1) SG11201901894TA (zh)
WO (1) WO2018041263A1 (zh)
ZA (1) ZA201901886B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276401A (zh) * 2017-01-05 2018-07-13 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN114127068A (zh) * 2019-07-22 2022-03-01 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN110627784B (zh) * 2016-09-05 2021-09-21 广东众生睿创生物科技有限公司 抗流感病毒嘧啶衍生物
WO2018108125A1 (en) 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
RU2769050C1 (ru) 2018-03-05 2022-03-28 Гуандун Рэйновент Байотек Ко., Лтд. Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN111454166B (zh) * 2019-12-30 2021-02-26 广东莱佛士制药技术有限公司 制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CN104922128A (zh) * 2009-06-17 2015-09-23 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN110627784B (zh) * 2016-09-05 2021-09-21 广东众生睿创生物科技有限公司 抗流感病毒嘧啶衍生物
RU2769050C1 (ru) * 2018-03-05 2022-03-28 Гуандун Рэйновент Байотек Ко., Лтд. Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104922128A (zh) * 2009-06-17 2015-09-23 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276401A (zh) * 2017-01-05 2018-07-13 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN114127068A (zh) * 2019-07-22 2022-03-01 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型

Also Published As

Publication number Publication date
EP3502112A1 (en) 2019-06-26
NZ751964A (en) 2021-02-26
CN110627784B (zh) 2021-09-21
IL265166A (en) 2019-05-30
US20230339943A1 (en) 2023-10-26
EP3502112A4 (en) 2019-06-26
KR20190056380A (ko) 2019-05-24
JP6838773B2 (ja) 2021-03-03
IL265166B (en) 2021-09-30
CN110623958A (zh) 2019-12-31
US11136319B2 (en) 2021-10-05
AU2017320088A1 (en) 2019-04-18
CA3035680C (en) 2023-05-02
CN109790159B (zh) 2020-01-14
US11725009B2 (en) 2023-08-15
US20220135558A1 (en) 2022-05-05
ZA201901886B (en) 2021-01-27
CN110623958B (zh) 2022-05-17
SG11201901894TA (en) 2019-04-29
WO2018041263A1 (zh) 2018-03-08
AU2017320088B2 (en) 2020-01-30
BR112019004420A2 (pt) 2019-05-28
KR102312088B1 (ko) 2021-10-14
RU2727772C1 (ru) 2020-07-23
JP2019529386A (ja) 2019-10-17
MX2019002541A (es) 2019-07-01
US20210032238A1 (en) 2021-02-04
CA3035680A1 (en) 2018-03-08
CN110627784A (zh) 2019-12-31

Similar Documents

Publication Publication Date Title
CN109790159A (zh) 抗流感病毒嘧啶衍生物
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109071448A (zh) Ask1抑制剂及其制备方法和应用
CN110944989B (zh) 作为egfr激酶抑制剂的芳基磷氧化合物
ES2614355T3 (es) Derivados de glicina N-sustituida con piridazin-diona como inhibidores de HIF hidoxilasas
JP2019529386A5 (zh)
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN106470992B (zh) 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
CN108602757B (zh) 地佐辛类似物
CN109311881A (zh) 新型β-内酰胺酶抑制剂
KR102547709B1 (ko) 아제티딘 유도체
AU2018208160B2 (en) HDAC6 selective inhibitors, preparation method therefor, and application thereof
CN109803951A (zh) 作为cccDNA抑制剂的磺酰胺类化合物
JP6951418B2 (ja) 抗ｈｃｍｖウイルス化合物
CN108884104A (zh) 作为免疫调节剂的三并环化合物
EA040139B1 (ru) Производное азитидина
BR112019017844B1 (pt) Composto derivado de azetidina, composição farmacêutica que o compreende e uso dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 3406a, jinzhonghuan international business building, 3037 Jintian Road, Fu'an community, Futian street, Futian District, Shenzhen City, Guangdong Province

Applicant after: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

Address before: Room 1701-1705, Main Building, Rongyi Building, No. 5 Information Road, Songshan Lake High-tech Industrial Development Zone, Dongguan City, Guangdong Province

Applicant before: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003826

Country of ref document: HK